You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Relapsed Acute Myeloid Leukemia

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Acute Myeloid Leukemia Trial in Beijing (Ven+CAG)

Recruiting
  • Acute Myeloid Leukemia
  • Beijing, Beijing, China
    Peking University People's Hospital
Jun 23, 2023

Relapsed Acute Myeloid Leukemia Trial in Saint Louis (Flotetuzumab, Donor lymphocyte infusion)

Recruiting
  • Relapsed Acute Myeloid Leukemia
  • Saint Louis, Missouri
    Washington University School of Medicine
Sep 7, 2022

Leukemia, Myeloid, Acute Trial (CD33KO-HSPC; CART33)

Not yet recruiting
  • Leukemia, Myeloid, Acute
  • CD33KO-HSPC; CART33
  • (no location specified)
Jul 13, 2023

Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia Recurrent Trial in Beijing (CD123-CAR-NK cells)

Recruiting
  • Acute Myeloid Leukemia Refractory
  • Acute Myeloid Leukemia Recurrent
  • CD123-CAR-NK cells
  • Beijing, Beijing, China
    The Fifth Medical Center of Chinese People's Liberation Army (PL
Oct 24, 2022

Acute Myeloid Leukemia Trial in Nanjing (Chidamide, Cladribine)

Recruiting
  • Acute Myeloid Leukemia
  • Nanjing, Jiangsu, China
    Department of Hematology, Zhongda Hospital Southeast University,
Apr 23, 2022

Acute Myeloid Leukemia, Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia Trial in Houston (Decitabine, Quizartinib,

Recruiting
  • Acute Myeloid Leukemia
  • +4 more
  • Houston, Texas
    M D Anderson Cancer Center
Jan 27, 2023

Recurrent Acute Myeloid Leukemia Trial in Nashville (Venetoclax, Decitabine, Cedazuridine)

Not yet recruiting
  • Recurrent Acute Myeloid Leukemia
  • Nashville, Tennessee
    Vanderbilt University/Ingram Cancer Center
Mar 22, 2023

Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Acute Myeloid Leukemia Trial in United States

Recruiting
  • Refractory Acute Myeloid Leukemia
  • +4 more
  • CD371-YSNVZ-IL18 CAR T cells
  • Basking Ridge, New Jersey
  • +6 more
Aug 29, 2023

Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, in Relapse Trial in Xuzhou (anti Tim-3/CD123 CAR-T cell therapy)

Recruiting
  • Acute Myeloid Leukemia Refractory
  • Acute Myeloid Leukemia, in Relapse
  • anti Tim-3/CD123 CAR-T cell therapy
  • Xuzhou, Jiangsu, China
    Kailin Xu
Nov 4, 2023

Acute Bilineal Leukemia, Acute Biphenotypic Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome

Recruiting
  • Acute Bilineal Leukemia
  • +8 more
  • Houston, Texas
    M D Anderson Cancer Center
Jan 24, 2023

Acute Myeloid Leukemia Trial in Pittsburgh (Neukoplast™ (NK-92))

Completed
  • Acute Myeloid Leukemia
  • Neukoplast™ (NK-92)
  • Pittsburgh, Pennsylvania
    UPMC Cancer Center - Hillman Cancer Center
Mar 28, 2022

Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory Trial (BP1002; Liposomal Bcl-2 Antisense

Not yet recruiting
  • Acute Myeloid Leukemia, in Relapse
  • Acute Myeloid Leukemia Refractory
  • BP1002; Liposomal Bcl-2 Antisense Oligodeoxynucleotide
  • Decitabine (in combination with BP1002)
  • (no location specified)
Mar 8, 2022

Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory Trial (CB-012)

Not yet recruiting
  • Acute Myeloid Leukemia, in Relapse
  • Acute Myeloid Leukemia Refractory
  • (no location specified)
Nov 9, 2023

Acute Myeloid Leukemia, Blastic Plasmacytoid Dendritic Cell Tumor (BPDCN), Relapse Leukemia Trial in Taiyuan (CD123 targeted

Recruiting
  • Acute Myeloid Leukemia
  • +3 more
  • CD123 targeted CAR-NK cells
  • Taiyuan, Shanxi, China
    Shanxi Bethune Hospital
Aug 28, 2023

AML, AML With Mutated NPM1, Hematologic Malignancy Trial (Ziftomenib, Fludarabine, Idarubicin)

Not yet recruiting
  • AML
  • +11 more
  • (no location specified)
Aug 14, 2023

Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial in United States (Lanraplenib,

Recruiting
  • Acute Myeloid Leukemia
  • +2 more
  • Los Angeles, California
  • +3 more
Aug 4, 2022

Minimal Residual Disease, Recurrent Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Recurrent Adult Acute Myeloid

Completed
  • Minimal Residual Disease
  • +3 more
  • Daratumumab
  • +2 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Mar 2, 2022

Relapsed/Refractory Acute Myeloid Leukemia Trial in Hangzhou (B7-H3 target, CAR gene modified gdT cell injection)

Recruiting
  • Relapsed/Refractory Acute Myeloid Leukemia
  • B7-H3 target, CAR gene modified gdT cell injection
  • Hangzhou, Zhejiang, China
    The First Affiliated Hospital， Zhejiang University School of Med
Feb 15, 2023

Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, Minimal Residual Disease Trial (Venetoclax, Decitabine,

Not yet recruiting
  • Relapsed Acute Myeloid Leukemia
  • +2 more
  • Venetoclax, Decitabine, Azacytidine, Cytarabine
  • (no location specified)
May 4, 2022

Acute Myeloid Leukemia, High-Risk and Very High-Risk MDS Trial (SGR-2921)

Not yet recruiting
  • Acute Myeloid Leukemia
  • High-Risk and Very High-Risk Myelodysplastic Syndromes
  • (no location specified)
Jul 25, 2023

Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, MDS Trial (biological, drug, procedure)

Withdrawn
  • Relapsed Acute Myeloid Leukemia
  • +2 more
  • Cytokine-induced memory-like NK cells
  • +4 more
  • (no location specified)
Feb 23, 2022

Acute Biphenotypic Leukemia, Acute Myeloid Leukemia, Mixed Phenotype Acute Leukemia Trial in Seattle (Cladribine, Cytarabine,

Recruiting
  • Acute Biphenotypic Leukemia
  • +11 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Oct 18, 2022

Acute Myeloid Leukemia Trial in Beijing (Dual CD33/CLL1 CAR T)

Recruiting
  • Acute Myeloid Leukemia
  • Dual CD33/CLL1 CAR T
  • Beijing, Beijing, China
    Beijing Boren Hospital
Feb 16, 2022

Relapsed or Refractory Acute Myeloid Leukemia Trial in Taiyuan (Selinexor, Homoharringtonine, Daunorubicin)

Recruiting
  • Relapsed or Refractory Acute Myeloid Leukemia
  • Taiyuan, Shanxi, China
    Tao Wang
Feb 9, 2023

Acute Myeloid Leukemia Trial (ABBV-787)

Not yet recruiting
  • Acute Myeloid Leukemia
  • (no location specified)
Sep 29, 2023